Eli Lilly and Company vs Vertex Pharmaceuticals Incorporated: A Gross Profit Performance Breakdown

Eli Lilly vs. Vertex: A Decade of Gross Profit Growth

__timestampEli Lilly and CompanyVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201414683100000519428000
Thursday, January 1, 201514921500000906794000
Friday, January 1, 2016155672000001491717000
Sunday, January 1, 2017168011000002213533000
Monday, January 1, 2018168116000002638058000
Tuesday, January 1, 2019175983000003615063000
Wednesday, January 1, 2020190565000005469383000
Friday, January 1, 2021210056000006670200000
Saturday, January 1, 2022219116000007850400000
Sunday, January 1, 2023270419000008607000000
Monday, January 1, 2024366244000019489600000
Loading chart...

Data in motion

A Decade of Gross Profit Growth: Eli Lilly vs. Vertex Pharmaceuticals

In the competitive landscape of the pharmaceutical industry, Eli Lilly and Vertex Pharmaceuticals have demonstrated remarkable growth in gross profit over the past decade. From 2014 to 2023, Eli Lilly's gross profit surged by approximately 84%, reaching a peak in 2023. This growth reflects the company's strategic innovations and market expansions. Meanwhile, Vertex Pharmaceuticals, known for its focus on transformative medicines, saw its gross profit increase by an impressive 1,557% during the same period, highlighting its rapid ascent in the biotech sector.

Key Insights

  • Eli Lilly: Consistent growth with a notable jump in 2023, indicating successful product launches and market penetration.
  • Vertex Pharmaceuticals: Exceptional growth trajectory, underscoring its leadership in niche markets.

This analysis provides a clear picture of how these two giants have navigated the evolving pharmaceutical landscape, setting benchmarks for future growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025